1 / 103
Télécharger la présentation

Cutaneous Manifestations of Connective Tissue Disease: Lupus, Dermatomyositis, and Scleroderma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cutaneous Manifestations Of Connective Tissue Disease(Lupus, Dermatomyositisand Scleroderma) Prof. Fahad AlSaifProfessor, Department of Dermatology, College of Medicine, King Saud University

  2. Objectives • Differentiate between the various types of CLE • How to diagnose and investigate CLE • Identify all of the current treatment options available for CLE • To learn how to diagnose and investigate dermatomyositis. • How to manage dermatomyositis. • To learn the presentation of morphea and systemic sclerosis and ways to  manage them

  3. 1 Cutaneous Lupus Erythematosus(CLE)

  4. Cutaneous Lupus Erythematosus (CLE) • Lupus Erythematosus (LE): is a chronic, autoimmune disease that includes a broad spectrum of signs and symptoms.  • LE is divided into: • systemic form (SLE) and cutaneous form (CLE). • They can occur both together or separately

  5. Cutaneous Lupus Erythematosus (CLE) • CLE has various subsets and wide-ranging of clinical manifestations • The cutaneous manifestations of LE can be divided based on histopathological findings into : 1- Histopathologicallyspecific CLE: • Acute cutaneous LE (ACLE) • Subacutecutaneous LE (SCLE) • Chronic cutaneous LE (DLE) 2- Histopathologicallynon-specific LE-skin manifestations which are not exclusive to LE disease 

  6. Cutaneous Lupus Erythematosus (CLE) EPIDEMIOLOGY • Incidence of CLE in Sweden and USA is 4/100,000. • The female to male ratio 3:1 for both DLE and SCLE • DLE is more common among African Americans and SCLE is more common among Caucasians. • DLE is the most common subset (80%).

  7. Cutaneous Lupus Erythematosus (CLE) PATHOGENESIS • CLE is multifactorial and polygenic. • Complex interactions between genetics, environment, and cells. • More than 25 risk loci have been identified. • Ultraviolet radiation(appears to initiate CLE lesion formation by inducing apoptosis, precipitating autoantigen presentation, and promoting cellular production of specific cytokines).

  8. Cutaneous Lupus Erythematosus (CLE) PATHOGENESIS • Autoantibodies are a well-known entity in CLE, but their exact role remains unclear. • Native skin cells implicated in CLE include keratinocytes and endothelial cells. • Smoking • Drug-induced subacute CLE and DLE: hydrochlorothiazide, terbinafine, TNF-α inhibitors, antiepileptic and proton-pump inhibitors. • 30% of SCLE are secondary to drugs.

  9. Cutaneous Lupus Erythematosus (CLE)  Histopathology  • Focal or continuous epidermal atrophy (in CDLE alternating acanthotic areas) • Follicular keratin plugs • Vacuolar degeneration along the dermoepidermal junction zone • Individual necrotic keratinocytes • Thickening of basement membrane • Abundant interstitial mucin deposits in the reticular dermis • Moderate to dense superficial and deep perivascular and periadnexal lymphocytic infiltrate

  10. LE-specific skin manifestations

  11. 1-Acute CLE: • Almost always associated with systemic disease • Localized (concentrated above the neck) or generalized • Malar rash or butterfly erythema is the most typical localized lesion, an erythema (and/or oedema) over the malar eminence with a tendency to spare the nasolabial folds

  12. 1-Acute CLE: • The generalized form of acute CLE is uncommon • Associated with a previous sun exposure • Preferably located to sun-exposed areas • Maculopapularrash of lupus • Photosensitive lupus dermatitis • Bullous lupus

  13. 2-Subacute CLE : • Photosensitivity • There are two morphologic variants of SCLE: 1- Psoriasiformtype 2- Annular, polycyclic type • SubacuteCLE is strongly associated with the anti- Ro/SSA  • 15-20% of SCLE patients also have other types of CLE lesions • 50% of SCLE patients fulfill the American College of Rheumatology (ACR) criteria for SLE

  14. NEONATAL LE : • Develops in fetuses whose mothers have anti-Ro/SSA and/or anti-La/SSB antibodies and more rarely Ribonucleoprotein (RNP) antibodies • Transmission of antibodies over the placenta which can cause congenital heart block and cutaneous manifestations • Resolve spontaneously as the titers of maternal antibodies degrade within the first 6 months

  15. NEONATAL LE : • Photosensitivity, hepatobiliary disease, hemolytic anemia and thrombocytopenia or leucopenia • Cutaneous symptoms include a SCLE-like rash, erythematosus, non-scarring annular plaques most typical occurrence in the face and especially peri-orbital (“raccoon or owl eye”)

  16. NEONATAL LE : • Annular plaques with fine scale – “Owl” eyes – Crusted papules with petechiae • DLE lesions • Facial involvement is most common • Photosensitivity • Angiomatouspapules or telangiectatic mats

  17. NEONATAL LE : • Complete Heart block – 90% • May result in congestive heart failure in early childhood and the need for pacemaker placement • Associated congenital heart defects – 30%

  18. 3-Chronic CLE: A- Discoid LE is the most common subtype of CCLE • 60-80% is localized above the neck and 20-40% is generalized (lesions both above and below the neck) • Scalp, ears and cheeks are the most commonly involved areas • Have a chronic course, less chance of remission • More difficult to control

  19. 3-Chronic CLE: B-Verrucous or hypertrophic LE • Wart-like lesions most often on the arms and/or hands • Typical DLE lesions elsewhere • Differential diagnosis – warts, KA, SCC

  20. 3-Chronic CLE: C- LE profundus (panniculitis): • Rare presentation of CCLE • Multiple subcutaneous nodules or plaques • Upper arms, shoulders, buttocks, or face. • DDx: Morpheaprofunda, erythema nodosum and subcutaneous panniculitis-like T-cell lymphoma

  21. 3-Chronic CLE: D- Chilblain Lupus • Rare form of CCLE • Predominantly in women • Occurs commonly on the digits, calves and heels • Microvascularinjury secondary to exposure to cold and possibly hyperviscosity from immunological abnormalities.  • Characterized by symmetrically erythematous to violaceous painful plaques over dorsal and lateral aspects of hands and feet, appearing during cold.

  22. 3-Chronic CLE: Lupus ErythematosusTumidus • Onset in summer • Photosensitivity > 70% • Histopathology – periadnexal, perivascular lymphocytic infiltrate with increased mucin • ANA < 10% • Systemic disease – 0

  23. Histopathologically non-specific LE-skin manifestations photosensitivity Vasculitis: Palpable and nonpalpablepurpura Urticarial-like vasculitisHypocomplementemic urticarial vasculitis Vasculopathy: Livedoreticularis , Erythromelalgia Urticaria Non-scarring alopecia: Oral lesions Bullous lesions Acanthosisnigricans

  24. Mucinous infiltration Porphyria cutaneatarda Psoriasis Other “autoimmune” disorders

  25. Differential diagnosis: CCLE: PS, sarcoidosis,LP SCLE : PMLE, rosacea, PS diseases, EAC, other figurate erythemas, DM Tumid LE : Sarcoid, BLI, PMLE, REM SLE : rosacea, drug-induced photosensitivity, DM

  26. Cutaneous Lupus Erythematosus (CLE)  Workup  • Goal: confirm diagnosis and assess for systemic involvement  • Thorough review of history and examination   • Skin biopsy: H&E and lesional DIF • Basic labs: CBC, LFT’s, creatinine, inflammatory markers (ESR, CRP), urinalysis  • Autoimmune serologies,: ANA, dsDNA, complement (C3, C4, total), anti-phospholipid Abs • If considering systemic therapy: Eye exam (antimalarials), hepatitis serologies (methotrexate), thiopurinemethyltransferase (TPMT; azathioprine 

  27. Cutaneous Lupus Erythematosus (CLE)   Management   Goal • Reassure the patient • Improve the patient’s appearance • Prevent the formation of scars, dyspigmentation and atrophy • Stop the formation of new lesions

  28. Cutaneous Lupus Erythematosus (CLE)   Management   TREATMENT A. Prevention • Patient education. • Heat, sun, and drug avoidance is standard • Strict sunscreen adherence is a critical component of therapy, as UVA and UVB irradiation has been shown to induce CLE lesions B. Topical Therapies • -steroids • -calcineurin inhibitors

More Related